

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

Product datasheet for TL305527V

CCR11 (ACKR4) Human shRNA Lentiviral Particle (Locus ID 51554)

Product data:

Product Type:	shRNA Lentiviral Particles
Product Name:	CCR11 (ACKR4) Human shRNA Lentiviral Particle (Locus ID 51554)
Locus ID:	51554
Synonyms:	CC-CKR-11; CCBP2; CCR-11; CCR10; CCR11; CCRL1; CCX-CKR; CCX CKR; CKR-11; PPR1; VSHK1
Vector:	pGFP-C-shLenti (TR30023)
Format:	Lentiviral particles
Components:	CCRL1 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.
RefSeq:	<u>NM_016557</u> , <u>NM_178445</u> , <u>NM_016557.1</u> , <u>NM_016557.2</u> , <u>NM_016557.3</u> , <u>NM_178445.1</u> , <u>NM_178445.2</u> , <u>BC069438</u> , <u>BC069438.1, BC095501</u> , <u>NM_016557.4</u>
UniProt ID:	Q9NPB9
Summary:	The protein encoded by this gene is a member of the G protein-coupled receptor family, and is a receptor for C-C type chemokines. This receptor has been shown to bind dendritic cell- and T cell-activated chemokines including CCL19/ELC, CCL21/SLC, and CCL25/TECK. A pseudogene of this gene is found on chromosome 6. Alternatively spliced transcript variants encoding the same protein have been described. [provided by RefSeq, Jul 2013]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u> . If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u> .



This product is to be used for laboratory only. Not for diagnostic or therapeutic use. ©2022 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US

CCR11 (ACKR4) Human shRNA Lentiviral Particle (Locus ID 51554) – TL305527V

Performance Guaranteed: OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).

This product is to be used for laboratory only. Not for diagnostic or therapeutic use. ©2022 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US